According to new studies, the coronavirus vaccine developed by Pfizer-BioNTech is “ extremely ” effective against 2 variants that are common and cause severe infections.
While the coronavirus pandemic , which affects the whole world , continues, scientific studies on the vaccines developed continue without slowing down. Now, according to new studies, the coronavirus vaccine developed by Pfizer-BioNTech is “ extremely ” effective against 2 variants that are common and cause severe infections .
According to clinical trials conducted on real patients in Qatar and Israel , the vaccine in question; It is extremely effective against B.1.1.7 strains first identified in England and B.1.351 strains first identified in South Africa. It is suggested that the relevant vaccine successfully prevented severe pneumonia (pneumonia) and deaths .
Previous studies have revealed various findings that the B.1.1.7 variant is more contagious and deadly, but it is stated that the vaccine developed by Pfizer-BioNTech is effective against the relevant strain. In addition, previous studies have shown that the vaccines are less effective against the B.1.351 strain.
In the new study published in the New England Journal of Medicine , Qatar ‘s national coronavirus database was examined and data including more than 200,000 people were analyzed.
As a result of the studies carried out , it was determined that the vaccine was 87 to 89.5 % effective against the B.1.1.7 strain . It should also be noted that the vaccine is 72.1 to 75% effective against the B.1.351 strain.
In another study published in Lancet journal , data of 230,000 people in Israel were analyzed and it was concluded that the vaccine was 95% effective against the B.1.1.7 strain .